Pseudorabies Virus Glycoproteins E and B Application in Vaccine and Diagnosis Kit Development
Vaccines · 20.09.2024 · 12 (9) · 1078
DOI: 10.3390/vaccines12091078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 20.09.2024. Verfasst von Sara Amanuel Bude und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou Veterinary Research Institute, Chinese Academ…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, the National Key R&D Program of China, the Key R&D and Conversion Plan.
Abstract (Originalsprache)
Background
Pseudorabies virus (PRV) is a highly infectious pathogen that affects a wide range of mammals and imposes a significant economic burden on the global pig industry. The viral envelope of PRV contains several glycoproteins, including glycoprotein E (gE) and glycoprotein B (gB), which play critical roles in immune recognition, vaccine development, and diagnostic procedures. Mutations in these glycoproteins may enhance virulence, highlighting the need for updated vaccines.
Method
This review examines the functions of PRV gE and gB in vaccine development and diagnostics, focusing on their roles in viral replication, immune system interaction, and pathogenicity. Additionally, we explore recent findings on the importance of gE deletion in attenuated vaccines and the potential of gB to induce immunity.
Results
Glycoprotein E (gE) is crucial for the virus’s axonal transport and nerve invasion, facilitating transmission to the central nervous system. Deletion of gE is a successful strategy in vaccine development, enhancing the immune response. Glycoprotein B (gB) plays a central role in viral replication and membrane fusion, aiding viral spread. Mutations in these glycoproteins may increase PRV virulence, complicating vaccine efficacy.
Conclusion
With PRV glycoproteins being essential to both vaccine development and diagnostic approaches, future research should focus on enhancing these components to address emerging PRV variants. Updated vaccines and diagnostic tools are critical for combating new, more virulent strains of PRV.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, China.
- College of Veterinary Medicine and Agriculture, Addis Ababa University, Bishoftu P.O. Box 34, Ethiopia.
ORCID-Profile: Sara Amanuel Bude
Förderung
- The National Natural Science Foundation of China
- the National Key R&D Program of China
- the Key R&D and Conversion Plan
- the Major Science and Technology Project of Gansu Province
- China Government Scholarship Council (CSC)
- National Natural Science Foundation of China
- National Key R&D Program of China
- Key R&D and Conversion Plan
Zitieren
APA
Bude, S. A., Lu, Z., Zhao, Z., & Zhang, Q. (2024). Pseudorabies Virus Glycoproteins E and B Application in Vaccine and Diagnosis Kit Development. Vaccines, 12(9), 1078. https://doi.org/10.3390/vaccines12091078
Vancouver
Bude SA, Lu Z, Zhao Z, Zhang Q. Pseudorabies Virus Glycoproteins E and B Application in Vaccine and Diagnosis Kit Development. Vaccines. 2024;12(9):1078. doi:10.3390/vaccines12091078
BibTeX
@article{Bude2024,
author = {Bude, Sara Amanuel and Lu, Zengjun and Zhao, Zhixun and Zhang, Qiang},
title = {Pseudorabies Virus Glycoproteins E and B Application in Vaccine and Diagnosis Kit Development},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {9},
pages = {1078},
doi = {10.3390/vaccines12091078}
}
EUVIMED